PTCTPTC Therapeutics, Inc.
Price
+7.0%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality mixed, nothing alarming, demanding price, growth steady, the market against it.
We are a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. We are advancing a robust and diversified pipeline of transformative medicines as part of our mission to provide access to best-in-class treatments for patients with unmet medical needs. Our strategy is to leverage our scientific expertise and global commercial infrastructure to optimize value for our patients and other stakeholders.
In the company’s own words · 10-K filed Feb 19, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
PTC Therapeutics, Inc. (PTCT) reported revenue of $361M in Q2 2026 (quarter ended Jun 30, 2026), up 102% from the same quarter a year earlier. That came with net income of $83M (23% of revenue). For the full year FY2025, revenue was $1.73B (+115% year on year) and net income $683M. Its largest product in Q2 2026 was Sephience at $128M, 38% of the disclosed total, ahead of Royalty at 21%. The next results filing is expected around Nov 3, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 21, 2026On September 21, 2026, the Company issued a press release announcing it completed the Acquisition. As previously disclosed, a rolling biologics license application (“BLA”) submission to the U.S. Food and Drug Administration for accelerated approval of ST-920 is expected to be completed in the fourth quarter of 2026.Regulation FD disclosure · Form 8-K
- Aug 28, 2026On August 25, 2026, PTC Therapeutics, Inc. (the “Company”) entered into an asset purchase agreement (the “Asset Purchase Agreement”) with Sangamo Therapeutics, Inc. (“Sangamo”), pursuant to which the Company agreed to acquire from Sangamo, subject to the terms and conditions set forth in the Asset Purchase Agreement …Material agreement entered · Form 8-K
- Aug 13, 2026On August 12, 2026, the Company issued a press release in which it announced the planned Acquisition.Regulation FD disclosure · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $336.8MThe company’s own SEC segment disclosure.
- Sephience$127.5M38%
- Royalty$71.1M21%
- Collaboration And License$50.6M15%
- Translarna$42.2M13%
- Emflaza$24.6M7%
- Upstaza And Kebilidi$11.2M3%
- Other (1)$9.5M3%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.